Lactate Metabolism and MCT Transporters
Four Processes, One Measurement
| Process | Direction | Driver | Consequence |
|---|---|---|---|
| Production | Pyruvate → lactate | LDH-A; NADH availability | Regenerates NAD⁺; acidifies cytosol |
| Export | Intracellular → extracellular | MCT4 (low affinity, high capacity) | Removes lactate and a proton |
| Import | Extracellular → intracellular | MCT1 (high affinity) | Supplies oxidative substrate |
| Oxidation | Lactate → pyruvate → TCA | LDH-B; mitochondrial LDH | Fuel; requires NAD⁺ regeneration downstream |
Important distinction. A fall in medium lactate can mean reduced production, increased export, increased import, or increased oxidation. These are four different biological events with different implications, and a single medium measurement cannot distinguish them.
The distinction matters most in two situations: cells that both produce and consume lactate at high rates (many tumour lines in standard medium), and experiments in which the medium already contains lactate (most sera, and many formulations).
Part 1 — The Transporters
| Transporter | Gene | Kinetics | Typical role |
|---|---|---|---|
| MCT1 | SLC16A1 | High affinity, lower capacity | Lactate uptake; oxidative cells |
| MCT2 | SLC16A7 | Highest affinity | Neurons; low-Km tissues |
| MCT3 | SLC16A8 | Retinal pigment epithelium | Specialised |
| MCT4 | SLC16A3 | Low affinity, high capacity | Lactate export from glycolytic cells |
| Basigin (CD147) | BSG | Chaperone for MCT1 and MCT4 | Required for surface expression |
Caveat on inhibitor specificity. The commonly used MCT inhibitors (AZD3965 for MCT1, AR-C155858 for MCT1/2, α-cyano-4-hydroxycinnamate for several MCTs) differ in selectivity and in potency, and several also affect mitochondrial pyruvate transport at higher concentrations. A phenotype produced by an MCT inhibitor establishes that a monocarboxylate transporter was involved, not which one.
The basigin dependence is a useful genetic handle: BSG loss reduces surface MCT1 and MCT4 together, which produces a stronger phenotype than either alone and is often the cleaner experiment for a transport claim.
Part 2 — What Each Measurement Reports
| Measurement | Reports | Does not report |
|---|---|---|
| Medium lactate at one timepoint | Net accumulation to that point | Production rate; direction of flux |
| Lactate at two timepoints (rate) | Net release rate over the interval | Gross production or consumption |
| Lactate/glucose molar ratio | Fraction of glucose carbon exported as lactate | Absolute flux; contribution of other substrates |
| ¹³C-glucose to ¹³C-lactate | Glucose-derived lactate production | Lactate produced from glutamine or glycogen |
| ¹³C-lactate to ¹³C-TCA intermediates | Oxidation of extracellular lactate | Endogenous lactate oxidation |
| Extracellular acidification | Net proton export | Lactate specifically; CO₂ contributes |
Readout note. The most informative single experiment for a lactate claim is a tracer pair: ¹³C-glucose to measure production and ¹³C-lactate to measure oxidation, performed in the same medium and the same window. Net release is then interpretable as the difference between two measured gross rates rather than as an inference.
A common error is to treat a high lactate/glucose ratio as evidence of high glycolytic flux. The ratio reports partition, not rate; a slow cell that exports all of its glycolytic pyruvate as lactate has a high ratio and a low flux.
Part 3 — Lactate as Fuel
Lactate oxidation requires three things that are often assumed rather than shown: uptake, conversion to pyruvate with NAD⁺ regeneration, and mitochondrial oxidation of that pyruvate.
| Requirement | How to test | Note |
|---|---|---|
| Uptake | MCT1 dependence; ¹³C-lactate disappearance from medium | Export can mask uptake in net measurements |
| Conversion | ¹³C-lactate to ¹³C-pyruvate and ¹³C-alanine | LDH-B direction depends on the NAD⁺/NADH ratio |
| Oxidation | ¹³C-lactate to ¹³C-citrate, malate, aspartate | Requires mitochondrial pyruvate entry; MPC dependence |
| Dependence | Growth in lactate as the principal substrate, with MCT1 or MPC loss | The strongest form of the claim |
The fourth row is what separates "lactate can be oxidised" from "lactate supports the cell". Many lines oxidise labelled lactate at a measurable rate while remaining dependent on glucose for survival; the two statements are compatible and only the second has physiological content.
Part 4 — Lactate as a Signal
Lactate has been reported to act through several mechanisms, and the evidence standards differ.
| Mechanism | Evidence required | Common weakness |
|---|---|---|
| Receptor-mediated signalling (for example HCAR1) | Receptor dependence; a response in a receptor-null background | Lactate concentrations far above physiological |
| Protein modification (lactylation) | Site-resolved identification; dependence on lactate production; non-modifiable mutant | Mark–phenotype correlation without a mutant |
| Redox effects | Compartment-specific NADH measurement | Bulk ratios average compartments |
| pH effects | Buffered controls at matched pH | Acidification attributed to lactate |
Caveat on concentration. Many signalling experiments use lactate at 10–30 mM, which is far above typical culture concentrations and above most tissue concentrations. A response at 25 mM establishes that lactate can do something at 25 mM, and the physiological relevance requires a dose–response that includes the relevant range.
The fourth row is the control most often missing: lactate export carries a proton, so any lactate manipulation also changes pH unless the medium is buffered and the pH is measured.
Part 5 — Three Levels of Evidence
| Level | Claim | Minimum evidence | What does not count |
|---|---|---|---|
| 1. Net exchange | Medium lactate changed | Calibrated measurement at two timepoints, normalised | A single endpoint |
| 2. Gross flux | Production or oxidation changed | Tracer measurement of the specific direction | Net release; the lactate/glucose ratio |
| 3. Dependence | Lactate handling is required for a phenotype | Transporter or enzyme perturbation under a constraint, with rescue | Correlation between medium lactate and growth |
Part 6 — Model Requirements and Recurring Failures
| Requirement | Why |
|---|---|
| Medium lactate baseline measured | Serum and formulations contain lactate |
| Medium volume and sampling time recorded | Net rates require both |
| Buffering and pH measured | Lactate export acidifies the medium |
| Glucose and glutamine concentrations documented | Both contribute to the lactate pool |
| Cell number and viability at harvest | Lactate release tracks viable biomass |
| Oxygen tension documented | Determines the partition toward export |
Recurring failures:
- • Net release reported as production.
- • The lactate/glucose ratio reported as glycolytic rate.
- • Lactate attributed to glucose when glutamine-derived lactate was not excluded.
- • MCT inhibitor phenotype attributed to a specific isoform without genetic confirmation.
- • Signalling effects reported at supraphysiological concentrations without a dose–response.
- • pH not controlled in lactate supplementation experiments.
- • Lactate consumption ignored in long experiments, where the medium concentration can plateau or fall.
Part 7 — Where This Article Connects
Lactate is the junction between the pillar's glycolytic module and its oxidative module: it is where the partition decision becomes visible, and where the redox constraint of glycolysis is satisfied. The switch article covers the partition logic; the enzyme article covers LDHA; and the assay-selection article in this cluster covers the analytical methods for measuring lactate itself.
If you need lactate flux resolved into production and oxidation rather than net release, we can scope the design with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
Transporter expression, lactate production and oxidation rates vary with cell type, medium, oxygen tension and density; the directions described here are common patterns, not fixed relationships.
A change in medium lactate does not establish a change in production, and a change in production does not establish that lactate is required for a phenotype.
Scientific interpretation and experimental design
- • Four processes, one number. Net release is not production.
- • Trace both directions. ¹³C-glucose and ¹³C-lactate in the same window.
- • The ratio is partition, not rate.
- • MCT inhibitors are not isoform-specific. Use genetic confirmation.
- • Baseline lactate is in the medium. Measure it before the experiment.
- • Lactate carries a proton. Control pH in any supplementation design.
- • Signalling needs a physiological dose range.
Selected references for further reading
- • Halestrap AP. The SLC16 gene family — structure, role and regulation in health and disease. Molecular Aspects of Medicine. 2013;34:337–349.
- • Hui S, et al. Glucose feeds the TCA cycle via circulating lactate. Nature. 2017;551:115–118.
- • Rabinowitz JD, Enerbäck S. Lactate: the ugly duckling of energy metabolism. Nature Metabolism. 2020;2:566–571.
- • Certo M, et al. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nature Reviews Immunology. 2021;21:151–161.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »